{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:46:16Z","timestamp":1788435976445,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.bbrc.2025.151967","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T10:55:14Z","timestamp":1747133714000},"page":"151967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Assessment of innate immune response modulating impurities (IIRMI) in synthetic peptide drugs (liraglutide)"],"prefix":"10.1016","volume":"771","author":[{"given":"Yangming","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7479-8383","authenticated-orcid":false,"given":"Xiaojie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhui","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bbrc.2025.151967_bib2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in peptide drug discovery","volume":"20","author":"Muttenthaler","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2025.151967_bib3","series-title":"Immunogenicity Testing of Therapeutic Protein Products-Developing and Validating Assays for Anti-drug Antibody Detection","year":"2019"},{"key":"10.1016\/j.bbrc.2025.151967_bib4","unstructured":"Guidelineon Immunogenicity Assessment of biotechnology-derived Therapeutic Proteins (EMEA\/CHMP\/BMWP\/14327\/2006 Rev 1), 1st Dec 2017."},{"issue":"3","key":"10.1016\/j.bbrc.2025.151967_bib5","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.clim.2013.09.006","article-title":"T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation","volume":"149","author":"Jawa","year":"2013","journal-title":"Clin. Immunol."},{"issue":"Suppl 5","key":"10.1016\/j.bbrc.2025.151967_bib6","doi-asserted-by":"crossref","first-page":"v9","DOI":"10.1093\/ndt\/gfl476","article-title":"Immunogenicity of biopharmaceuticals","volume":"21","author":"Kessler","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"issue":"2","key":"10.1016\/j.bbrc.2025.151967_bib7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.biologicals.2011.01.006","article-title":"Taking immunogenicity assessment of therapeutic proteins to the next level","volume":"39","author":"B\u00fcttel","year":"2011","journal-title":"Biologicals"},{"key":"10.1016\/j.bbrc.2025.151967_bib8","first-page":"3","article-title":"An overview of scientific and regulatory issues for the immunogenicity of biological products","volume":"112","author":"Chamberlain","year":"2003","journal-title":"Dev. Biol."},{"issue":"6","key":"10.1016\/j.bbrc.2025.151967_bib9","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.tibtech.2006.04.001","article-title":"Scientific and regulatory considerations on the immunogenicity of biologics","volume":"24","author":"Shankar","year":"2006","journal-title":"Trends Biotechnol."},{"issue":"6","key":"10.1016\/j.bbrc.2025.151967_bib10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40262-015-0343-6","article-title":"Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics","volume":"55","author":"Jacobsen","year":"2016","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.bbrc.2025.151967_bib11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.bbrc.2025.151967_bib12","doi-asserted-by":"crossref","first-page":"498","DOI":"10.2337\/dc12-0709","article-title":"The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial","volume":"36","author":"Rosenstock","year":"2013","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.bbrc.2025.151967_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125078","article-title":"Detection of innate immune response modulating impurities in therapeutic proteins","volume":"10","author":"Haile","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2025.151967_bib14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-immunol-032414-112240","article-title":"Innate immune pattern recognition: a cell biological perspective","volume":"33","author":"Brubaker","year":"2015","journal-title":"Annu. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.bbrc.2025.151967_bib15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.bbrc.2009.08.062","article-title":"Toll-like receptors and innate immunity","volume":"388","author":"Kumar","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.bbrc.2025.151967_bib16","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1128\/CMR.00046-08","article-title":"Pathogen recognition and inflammatory signaling in innate immune defenses","volume":"22","author":"Mogensen","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.bbrc.2025.151967_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.cellbio.21.122303.115827","article-title":"Recognition and signaling by toll-like receptors","volume":"22","author":"West","year":"2006","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.bbrc.2025.151967_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev.pathol.4.110807.092239","article-title":"NOD-Like receptors: role in innate immunity and inflammatory disease","volume":"4","author":"Chen","year":"2009","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.bbrc.2025.151967_bib19","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1146\/annurev-immunol-020711-074929","article-title":"Molecular control of steady-state dendritic cell maturation and immune homeostasis","volume":"31","author":"Hammer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"issue":"14","key":"10.1016\/j.bbrc.2025.151967_bib20","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1182\/blood-2011-07-368720","article-title":"Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation","volume":"120","author":"Brennan","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bbrc.2025.151967_bib21","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1073\/pnas.0608745104","article-title":"Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to toll-like receptor 9","volume":"104","author":"Parroche","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"23","key":"10.1016\/j.bbrc.2025.151967_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01219-18","article-title":"Toll-like receptor 7 (TLR-7) and TLR-9 agonists improve hepatitis C virus replication and infectivity inhibition by plasmacytoid dendritic cells","volume":"92","author":"Dominguez-Molina","year":"2018","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.bbrc.2025.151967_bib23","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.it.2006.06.003","article-title":"NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity","volume":"27","author":"Creagh","year":"2006","journal-title":"Trends Immunol."},{"issue":"2","key":"10.1016\/j.bbrc.2025.151967_bib24","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/jps.22276","article-title":"Impact of product-related factors on immunogenicity of biotherapeutics","volume":"100","author":"Singh","year":"2011","journal-title":"J. Pharmaceut. Sci."},{"issue":"12","key":"10.1016\/j.bbrc.2025.151967_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015252","article-title":"Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins","volume":"5","author":"Verthelyi","year":"2010","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bbrc.2025.151967_bib26","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.anai.2018.02.018","article-title":"Xolair-induced recurrent anaphylaxis through sensitization to the excipient polysorbate","volume":"120","author":"Perino","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"5","key":"10.1016\/j.bbrc.2025.151967_bib27","first-page":"562","article-title":"Immediate hypersensitivity to mannitol: a potential cause of apparent hypersensitivity to cisplatin","volume":"69","author":"Ackland","year":"1985","journal-title":"Cancer Treat Rep."},{"issue":"5","key":"10.1016\/j.bbrc.2025.151967_bib28","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/archopht.1967.00980030585004","article-title":"Anaphylactic reaction to mannitol","volume":"78","author":"Spaeth","year":"1967","journal-title":"Arch. Ophthalmol."},{"issue":"5 Pt 1","key":"10.1016\/j.bbrc.2025.151967_bib29","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/0091-6749(84)90514-1","article-title":"In vitro basophil histamine release induced by mannitol in a patient with a mannitol-induced anaphylactoid reaction","volume":"73","author":"Findlay","year":"1984","journal-title":"J. Allergy Clin. Immunol."},{"issue":"11","key":"10.1016\/j.bbrc.2025.151967_bib30","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1016\/j.xphs.2018.07.016","article-title":"Are injection site reactions in monoclonal antibody therapies caused by polysorbate excipient degradants?","volume":"107","author":"Singh","year":"2018","journal-title":"J. Pharmaceut. Sci."},{"issue":"3","key":"10.1016\/j.bbrc.2025.151967_bib31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1440-1797.2005.00389.x","article-title":"Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin","volume":"10","author":"Steele","year":"2005","journal-title":"Nephrology"},{"key":"10.1016\/j.bbrc.2025.151967_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.970499","article-title":"Detection of innate immune response modulating impurities (IIRMI) in therapeutic peptides and proteins: impact of excipients","volume":"13","author":"Thacker","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bbrc.2025.151967_bib33","first-page":"588","article-title":"Evaluation of the in vitro pyrogen test system based on proinflammatory cytokine release from human monocytes: comparison with a human whole blood culture test system and with the rabbit pyrogen test","volume":"9","author":"Nakagawa","year":"2002","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.bbrc.2025.151967_bib34","first-page":"121","article-title":"Assay of pyrogenic contamination in pharmaceuticals by cytokine release from monocytes","volume":"69","author":"Poole","year":"1988","journal-title":"Dev. Biol. Stand."},{"issue":"24","key":"10.1016\/j.bbrc.2025.151967_bib35","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.3390\/molecules26247461","article-title":"An in vitro assessment of immunostimulatory responses to ten model innate immune response modulating impurities (IIRMIs) and peptide drug product, teriparatide","volume":"26","author":"Holley","year":"2021","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.bbrc.2025.151967_bib36","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.xphs.2020.12.003","article-title":"The impact of product and process related critical quality attributes on immunogenicity and adverse immunological effects of biotherapeutics","volume":"110","author":"Wen","year":"2021","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.bbrc.2025.151967_bib37","unstructured":"The ICH Guidance Q3C Impurities: Residual Solvents Recommends Acceptable Amounts for Residual Solvents in Pharmaceuticals for the Safety of the Patient. the ICH Guidance Q3D Elemental Impurities Presents a Process to Assess and Control Elemental Impurities in the Drug Product Using the Principles of Risk Management Described in ICH Q9."},{"issue":"7","key":"10.1016\/j.bbrc.2025.151967_bib38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11095-020-02817-9","article-title":"Influence of production process and scale on quality of polypeptide drugs: a case study on GLP-1 analogs","volume":"37","author":"Staby","year":"2020","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.bbrc.2025.151967_bib39","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.xphs.2015.11.002","article-title":"Immunogenicity of therapeutic protein aggregates","volume":"105","author":"Moussa","year":"2016","journal-title":"J. Pharmaceut. Sci."},{"issue":"7","key":"10.1016\/j.bbrc.2025.151967_bib40","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1007\/s11095-016-1914-4","article-title":"Physical characterization and innate immunogenicity of aggregated intravenous Immunoglobulin (IGIV) in an In vitro cell-based model","volume":"33","author":"Moussa","year":"2016","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.bbrc.2025.151967_bib41","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.xphs.2019.01.015","article-title":"Impact of precipitation of antibody therapeutics after subcutaneous injection on pharmacokinetics and immunogenicity","volume":"108","author":"Kinderman","year":"2019","journal-title":"J. Pharmaceut. Sci."},{"issue":"7335","key":"10.1016\/j.bbrc.2025.151967_bib42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature09737","article-title":"Programming the magnitude and persistence of antibody responses with innate immunity","volume":"470","author":"Kasturi","year":"2011","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bbrc.2025.151967_bib43","doi-asserted-by":"crossref","first-page":"352","DOI":"10.14573\/altex.2013.3.352","article-title":"Evidence for the detection of non-endotoxin pyrogens by the whole blood monocyte activation test [published correction appears in","volume":"30","author":"Hasiwa","year":"2013","journal-title":"ALTEX"},{"key":"10.1016\/j.bbrc.2025.151967_bib44","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jpba.2013.03.011","article-title":"Comparison of limulus amebocyte lysate test methods for endotoxin measurement in protein solutions","volume":"80","author":"Chen","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"5","key":"10.1016\/j.bbrc.2025.151967_bib45","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1177\/1753425912436590","article-title":"A bioassay for determination of lipopolysaccharide in environmental samples","volume":"18","author":"Peters","year":"2012","journal-title":"Innate Immun."},{"issue":"11","key":"10.1016\/j.bbrc.2025.151967_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277922","article-title":"Assessment of innate immune response modulating impurities in glucagon for injection","volume":"17","author":"Han","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2025.151967_bib47","unstructured":"ICH Q2 (R1) Validation of analytical procedures: text and methodology, Available at: (http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q2_R1\/Step4\/Q2_R1__Guideline.pdf) Current step version dated 27 october 1994."},{"key":"10.1016\/j.bbrc.2025.151967_bib48","series-title":"Adminsitration; Fad. U.S. Department of Health and Human ServicesSilver Spring, Maryland: Food and Drug Administration","article-title":"Guidance for industry: ANDAs for certain highly purified synthetic peptides drug products that reference peptide drug products of rDNA origin","year":"2021"},{"key":"10.1016\/j.bbrc.2025.151967_bib49","article-title":"Guidance for industry: immunogenicity assessment for therapeutic protein products. U.S. department of health and human services","year":"2014","journal-title":"Food and Drug Administration"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25006813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25006813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:34:43Z","timestamp":1787776483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X25006813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":48,"alternative-id":["S0006291X25006813"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.151967","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of innate immune response modulating impurities (IIRMI) in synthetic peptide drugs (liraglutide)","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.151967","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151967"}}